GlassScriptPhysician profile
Christopher R Durando
NPI 1376598276
$5,943.67
in general payments reported to CMS, 2019-2025
38 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $544 · 2021: $1,245 · 2022: $1,016 · 2023: $934 · 2024: $763 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,476.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $837.65 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $749.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $744.61 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $438.01 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $422.88 | 2020-2025 | Ebglyss, Mounjaro, Jardiance |
| Pfizer INC. | $337.67 | 2019-2025 | |
| Novo Nordisk INC | $306.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $305.03 | 2021-2025 | |
| Abbvie INC. | $219.58 | 2021-2025 | Vraylar |
| Esperion Therapeutics, INC. | $213.19 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $174.33 | 2019-2021 | |
| Exact Sciences Corporation | $107.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $98.28 | 2022-2023 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Merck Sharp & Dohme LLC | $94.81 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $90.93 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Durando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.